Skip to main content
VERU
NASDAQ Life Sciences

Shareholders Approve Significant Increase in Equity Incentive Plan Shares

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$2.39
Mkt Cap
$38.36M
52W Low
$2.1
52W High
$7.4
52W Position info
14% above low
Off High info
68% below high
Rel. Volume info
0.2× avg
Market data snapshot near publication time

VERU is trading near its 52-week low of $2.1 (14% above the low) on light trading volume (0.2× avg).

Summary

VERU INC. shareholders approved an amendment to the 2018 Equity Incentive Plan, significantly increasing the number of shares authorized for future equity awards, which could lead to substantial dilution.


Key Events · Financing and Capital Events · VERU

  • Significant Equity Incentive Plan Expansion

    Shareholders approved an amendment to the 2018 Equity Incentive Plan, increasing the total shares authorized for issuance from 2,600,000 to 5,850,000. If all authorized shares were issued, potential dilution would be approximately 36.45%.

  • Increased Annual Award Limits

    The annual limit on awards to participants (other than non-employee directors) was raised from 100,000 to 750,000 shares, and for non-employee directors from 10,000 to 120,000 shares.

  • Routine Annual Meeting Outcomes

    All nominated directors were elected, Cherry Bekaert LLP was ratified as the independent registered public accounting firm, and executive compensation received advisory approval.


Analysis · VERU · Life Sciences

The approval of the amended Equity Incentive Plan significantly increases the number of shares authorized for future equity awards from 2,600,000 to 5,850,000. If all 5,850,000 shares were issued, it would result in a potential dilution of approximately 36.45% relative to the current outstanding shares (16,050,320 shares eligible to vote). This substantial expansion of the equity pool for compensation and incentives, especially in light of the company's recent highly dilutive public offering and a going concern warning, indicates a continued reliance on equity-based mechanisms that could exert downward pressure on the stock. Investors should closely monitor the actual issuance of these shares.

At the time of this filing, VERU was trading at $2.39 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $38.4M. The 52-week trading range was $2.10 to $7.40. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

VERU - Latest Insights

VERU
Jul 02, 2026, 4:13 PM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $2.97
Real-time Price: $2.25 info
Change: -$0.720 (-24%) info
Market Cap: $36.113M info
VERU
Jul 02, 2026, 4:08 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $2.97
Real-time Price: $2.25 info
Change: -$0.720 (-24%) info
Market Cap: $36.113M info
VERU
Jul 02, 2026, 4:05 PM EDT
Filing Type: 424B5
Importance Score:
9
Price at Filing: $3.06
Real-time Price: $2.25 info
Change: -$0.810 (-26%) info
Market Cap: $36.113M info
VERU
Jun 04, 2026, 10:57 PM EDT
Source: dpa-AFX
Importance Score:
9
Price at Filing: $3.77
Real-time Price: $2.25 info
Change: -$1.52 (-40%) info
Market Cap: $36.113M info
VERU
Jun 04, 2026, 8:30 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.25
Real-time Price: $2.25 info
Change: $0 (0%) info
Market Cap: $36.113M info